News archive

May 2018

• Media ReleaseMay 30, 2018
  FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)
• Media ReleaseMay 28, 2018
  Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®
  - Overall summary score was also significantly higher for Entresto patients than for patients not taking Entresto, as measured by the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12)1-…
• Media ReleaseMay 28, 2018
  Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®
• Media ReleaseMay 18, 2018
  Novartis and Amgen announce FDA approval of Aimovig™ (erenumab-aooe), a novel treatment developed specifically for migraine prevention
  - Migraine is a severe neurologic disease that profoundly impacts millions of patients in the United States- Aimovig is the first and only FDA-approved treatment to block the calcitonin gene-related…
• Media ReleaseMay 17, 2018
  Novartis and Amgen announce FDA approval of Aimovig™ (erenumab-aooe), a novel treatment developed specifically for migraine prevention
• Media ReleaseMay 17, 2018
  Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer
  - Results from the Kisqali® MONALEESA clinical trial program, the largest industry-sponsored Phase III registration program researching a CDK4/6 inhibitor in HR+/HER2- advanced breast cancer, will be…
• Media ReleaseMay 17, 2018
  Alcon teams up with Venus Williams, tennis champion and dry eye sufferer, to launch Systane® Complete eye drops
  The new product joins the #1 doctor recommended Systane family of dry eye drops as the brand's most advanced solution to dateAlcon launches multimedia campaign to reach the 30 million people living…
• Media ReleaseMay 17, 2018
  Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer
• Media ReleaseMay 17, 2018
  Alcon teams up with Venus Williams, tennis champion and dry eye sufferer, to launch Systane® Complete eye drops
• Media ReleaseMay 12, 2018
  Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
  - New approval for Gilenya (fingolimod) addresses strong unmet need for younger patients, who often experience more frequent relapses than adults with multiple sclerosis (MS)(1)- In a landmark…
• Media ReleaseMay 11, 2018
  Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
• Media ReleaseMay 01, 2018
  Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
  Kymriah demonstrated an overall response rate of 50%, with median duration of response not yet reached at the time of data cut-off, indicating sustainability of response1Kymriah is the only CAR-T…